VisionSearch Bio builds simulation-first medicine. MilanoQ, our lead platform, targets resistant cancers with safe natural compounds — validated in silico before a single dose.
Mutation-driven cancers like KRAS/NRAS Q61H relapse frequently, even after aggressive first-line therapy.
FOLFOX and FOLFIRI suppress the immune system and cause serious organ stress.
Conventional chemotherapy fails to prevent long-term resistance and disease recurrence.
MilanoQ is a next-generation, immune-compatible, mutation-targeted therapeutic system — built entirely from safe, natural compounds and designed to work with the body, not against it.
Designed to engage resistant driver mutations such as NRAS/KRAS Q61H directly.
Drives programmed tumor-cell death at an IC50 of ~11.5 µM in modeling.
Restores CD8+ T-cell activity (~4.1×) — normally the domain of biologics.
Suppresses mutation escape (<4%) for durable, long-term control.
One of the most deeply modeled non-toxic oncology platforms in development — validated across quantum pharmacology, immune mapping, and whole-body microdosing.
Molecular binding modeled with Qiskit + PennyLane for precision before synthesis.
Tumor–immune ecosystem modeling of how the therapy reshapes the microenvironment.
T-cell exhaustion horizon modeling to predict durability of immune response.
Whole-body microdosing map projecting distribution and exposure across tissues.
1,000-avatar simulated cohort to stress-test response and variability.
Organoid modeling plus enteric-coated delivery simulation (~87% bioavailability).
MilanoQ has demonstrated performance and/or is actively being evaluated across a broad set of hard-to-treat indications.
CRO-led preclinical validation, dendritic-cell-vaccine integration, and IND-enabling studies. The full technical case is in the white paper.
Whether you're an investor, a CRO, or a strategic partner — we'd love to share the deeper data and discuss collaboration.